GHRP · GHS-R1a agonist · Spoke 3.13

GHRP-6: a potent GH secretagogue with a selectivity problem — cortisol, prolactin, and appetite effects that distinguish it from newer GHRPs.

Q: Does GHRP-6 increase appetite significantly?

Yes. GHRP-6 is a full ghrelin receptor agonist. Ghrelin is the primary appetite-stimulating hormone. GHRP-6 reliably produces significant appetite stimulation, typically peaking 1–2 hours post-injection.

Q: What is the synergy between GHRP-6 and GHRH analogs?

GHRP-6 and GHRH analogs act via different receptors at the pituitary somatotroph. Combining them produces a supraadditive GH pulse — the pharmacological rationale for GHRP+GHRH combination protocols.

By PeptideRadar Research Desk · April 30, 2026

SequenceHis-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ (6 aa) MW873.0 Da Half-life~15–30 min SC TargetGHS-R1a (ghrelin receptor); also CD36 scavenger receptor Updated2026-04-30

GHRP-6 (growth hormone releasing peptide-6) is a synthetic hexapeptide and the first-generation GHS-R1a (ghrelin receptor) agonist developed specifically to stimulate growth hormone secretion. It preceded ipamorelin, GHRP-2, and hexarelin in the GHRP class and served as the pharmacological prototype for the category. GHRP-6 produces a large, reliable GH pulse — but also stimulates cortisol and prolactin release and produces a significant appetite-stimulating effect. These off-target activities define where it fits (or doesn't) in modern research peptide protocols.

Key points

First synthetic hexapeptide GHS-R1a agonist — the original prototype that led to the entire GHRP class.
Produces a large GH pulse (peak at ~30–60 min after SC injection). GH amplitude is dose-dependent with diminishing returns above ~100 mcg.
Co-stimulates ACTH/cortisol and prolactin release — the key selectivity difference from ipamorelin and sermorelin.
Strong appetite stimulation via ghrelin pathway — the most significant appetite effect in the GHRP class.
Published human PK and PD data exists — more than most research peptides in this category.
Tachyphylaxis (receptor desensitization) occurs with frequent dosing; pulsatile administration is standard.

The first-generation GHRP pharmacology

GHRP-6 was developed in the 1980s–1990s as the first purpose-designed GH secretagogue that operated via a pathway distinct from GHRH (growth hormone-releasing hormone). Where GHRH acts at pituitary somatotroph cells via the GHRH receptor to stimulate GH synthesis and release, GHRP-6 acts at the ghrelin receptor (GHS-R1a) — a GPCR that was later identified as the endogenous ghrelin receptor. The discovery of ghrelin in 1999 retroactively explained GHRP-6's mechanism.

At the GHS-R1a receptor, GHRP-6 is a full agonist with high affinity. The receptor is expressed at pituitary somatotrophs (mediating GH release) but also in the hypothalamus, gastrointestinal tract, and adipose tissue. The broad tissue expression explains why GHS-R1a agonism produces effects beyond GH release — including the appetite stimulation and cortisol effects that characterize GHRP-6.

GH pulse pharmacodynamics

Published human pharmacokinetic and pharmacodynamic studies of GHRP-6 provide one of the more complete evidence bases in the GHRP class:

Bowers et al. (1990s) published the foundational dose-response data showing that GHRP-6 at 1 mcg/kg SC produces peak GH levels at 30–60 minutes post-injection, with dose-response plateauing above approximately 1–2 mcg/kg (PMID: 8421098).
The GH pulse amplitude from GHRP-6 is synergistic with GHRH — combining GHRP-6 with CJC-1295 (a GHRH analog) produces a GH pulse significantly larger than either alone, establishing the rationale for the stacking approach.
Cordido et al. showed that GHRP-6 maintained its GH-stimulating effect in obese subjects where endogenous GH secretion is blunted — relevant for understanding GHRP-6 in different physiological contexts (PMID: 8405710).

The cortisol and prolactin problem

The critical pharmacological limitation of GHRP-6 compared to later GHRPs is its co-stimulation of the hypothalamic-pituitary-adrenal (HPA) axis. GHRP-6 stimulates ACTH release (via hypothalamic CRH mechanisms), which drives cortisol elevation. The cortisol response is dose-dependent and typically peaks alongside the GH pulse at 30–60 minutes post-injection.

Cortisol has catabolic effects in muscle tissue — promoting protein breakdown and inhibiting protein synthesis. The combination of anabolic (GH/IGF-1) and catabolic (cortisol) signaling from the same injection creates a pharmacological trade-off that reduces net anabolic benefit compared to a pure GH secretagogue. GHRP-2 has similar cortisol effects; ipamorelin and hexarelin have substantially less.

Prolactin elevation from GHRP-6 is a secondary concern — elevated prolactin can suppress testosterone (relevant for men) and cause other effects with chronic use. Again, ipamorelin's distinguishing feature is minimal prolactin stimulation at standard doses.

Appetite stimulation: the ghrelin effect

Ghrelin is the "hunger hormone" — endogenous ghrelin rises before meals and stimulates appetite via GHS-R1a in the hypothalamus. GHRP-6's agonism at this receptor produces the most pronounced appetite stimulation in the GHRP class. This is occasionally marketed as a feature ("great for hard gainers who struggle to eat"), but for most research contexts it represents an off-target effect that needs to be accounted for.

The appetite effect typically peaks at 1–2 hours post-injection and can be significant — reported food intake increases of 30–50% in some studies. This is a direct ghrelin-pathway effect and is pharmacologically expected rather than incidental.

GHRP-6 vs. ipamorelin: the selectivity comparison

The key reason ipamorelin has largely displaced GHRP-6 in modern research peptide protocols:

Parameter	GHRP-6	Ipamorelin
GH pulse amplitude	Large	Moderate-Large
Cortisol co-stimulation	Significant	Minimal
Prolactin co-stimulation	Moderate	Minimal
Appetite stimulation	Strong	Minimal
Receptor selectivity	Lower	Higher
Published human PK	Yes	Yes (Novo Nordisk)

Frequently asked

Why was GHRP-6 replaced by ipamorelin in most research protocols?

Ipamorelin selectively activates GHS-R1a for GH release without co-stimulating ACTH/cortisol and prolactin. GHRP-6 is a less selective agonist — it produces larger cortisol and prolactin responses alongside the GH pulse. For most anabolic or longevity research contexts, the cortisol elevation from GHRP-6 partially offsets the GH benefit.

Does GHRP-6 increase appetite significantly?

Yes. GHRP-6 is a full ghrelin receptor agonist; ghrelin is the primary appetite-stimulating hormone. GHRP-6 reliably produces significant appetite stimulation at standard doses, typically peaking 1–2 hours post-injection. This is mechanistically expected, not an unusual side effect.

What is the synergy between GHRP-6 and GHRH analogs?

GHRP-6 and GHRH (or GHRH analogs like CJC-1295 and sermorelin) act via different receptors at the pituitary somatotroph. Combining them produces a supraadditive GH pulse — significantly larger than either compound alone. This synergy is the pharmacological rationale for GHRP+GHRH combination protocols.

Is GHRP-6 detectable on drug tests?

WADA (World Anti-Doping Agency) prohibits all GH secretagogues including GHRP-6. Detection methods (mass spectrometry of urine or blood) have been developed and are used in competitive athletic testing. Research use outside of competitive sports is a separate consideration.

How does GHRP-6 compare to GHRP-2?

GHRP-2 is another first-generation GHRP with similar cortisol and prolactin co-stimulation to GHRP-6. GHRP-2 may have a slightly different receptor binding profile and is sometimes described as producing a larger GH pulse at equivalent doses. The selectivity profile difference between them is smaller than the difference between either and ipamorelin.

Reviewer sign-off Reviewed 2026-04-30 by the PeptideRadar Research Desk for RUO compliance, mechanism accuracy, and citation integrity. Corrections: corrections@peptideradar.net.